Cargando…

Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent

A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanaei Pirlar, Rima, Wagemans, Jeroen, Kunisch, Fabian, Lavigne, Rob, Trampuz, Andrej, Gonzalez Moreno, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612306/
https://www.ncbi.nlm.nih.gov/pubmed/36297651
http://dx.doi.org/10.3390/pharmaceutics14102216
_version_ 1784819742227300352
author Fanaei Pirlar, Rima
Wagemans, Jeroen
Kunisch, Fabian
Lavigne, Rob
Trampuz, Andrej
Gonzalez Moreno, Mercedes
author_facet Fanaei Pirlar, Rima
Wagemans, Jeroen
Kunisch, Fabian
Lavigne, Rob
Trampuz, Andrej
Gonzalez Moreno, Mercedes
author_sort Fanaei Pirlar, Rima
collection PubMed
description A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections.
format Online
Article
Text
id pubmed-9612306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96123062022-10-28 Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent Fanaei Pirlar, Rima Wagemans, Jeroen Kunisch, Fabian Lavigne, Rob Trampuz, Andrej Gonzalez Moreno, Mercedes Pharmaceutics Article A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections. MDPI 2022-10-18 /pmc/articles/PMC9612306/ /pubmed/36297651 http://dx.doi.org/10.3390/pharmaceutics14102216 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fanaei Pirlar, Rima
Wagemans, Jeroen
Kunisch, Fabian
Lavigne, Rob
Trampuz, Andrej
Gonzalez Moreno, Mercedes
Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title_full Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title_fullStr Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title_full_unstemmed Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title_short Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
title_sort novel stenotrophomonas maltophilia bacteriophage as potential therapeutic agent
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612306/
https://www.ncbi.nlm.nih.gov/pubmed/36297651
http://dx.doi.org/10.3390/pharmaceutics14102216
work_keys_str_mv AT fanaeipirlarrima novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent
AT wagemansjeroen novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent
AT kunischfabian novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent
AT lavignerob novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent
AT trampuzandrej novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent
AT gonzalezmorenomercedes novelstenotrophomonasmaltophiliabacteriophageaspotentialtherapeuticagent